ArticleFrontiers in pharmacology2026

Multidimensional lipid and inflammatory risk control following evolocumab treatment in real-world ASCVD: a hospital-based cohort study.

Qiang Niu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.